Inflammatory pain of the locomotor system Review article
Main Article Content
Abstract
Tissue damage is a result of an injury or disease process, and releases a cascade of mediators leading to the inflammation, sensitization processes in the nervous system, this consequently lead to the formation of an inflammatory pain component. Inflammatory pain is a consequence of the body’s defensive response. The inflammatory pain component is present in both acute and chronic pain syndromes. Most often, inflammatory pain affects the musculoskeletal system and is associated with osteoarthritis or takes the form of pains in the lower spine. Characteric for the inflammatory pain in the locomotor system is no improvement after rest (this differs from somatic overload, mechanical pain) and intensification at night, especially in its second part. Due to the complex pathomechanism of inflammatory pain, its treatment must be multimodal, and properly selected, contextual pharmacotherapy is one of the key elements of treatment.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Kopka M. Bóle w dolnym odcinku kręgosłupa – przegląd literatury. Ból. 2019; 20(3): 51-9.
3. Yennurajalingam S, Bruera E. Oxford American Handbook of hospice and palliative medicine and supportive care. Oxford University Press, Oxford 2016.
4. Woroń J, Wordliczek J, Malec-Milewska M. Farmakoterapia bólu. Analgetyki nieopioidowe wykazujące działanie przeciwzapalne. In: Dobrogowski J, Wordliczek J, Kocot-Kępska M (ed). Ból – Wiedza w kieszeni. Termedia, Poznań 2020: 41-50.
5. Woroń J. Nieopiodowe leki przeciwbólowe w leczeniu bólu. In: Malec-Milewska M, Woroń J (ed). Kompendium leczenia bólu. Medical Education, Warszawa 2017: 23-43.
6. Wordliczek J, Woroń J, Dobrogowski J. Nieopioidowe leki przeciwbólowe. In: Wordliczek J, Dobrogowski J (ed). Leczenie bólu. PZWL, Warszawa 2017: 36-53.
7. Shear NH. Drug Eruption & Reaction Manual. CRC Press, Boca Ration 2020.
8. Woroń J. Dobór leków z grupy NLPZ do profilu pacjenta – na co zwrócić uwagę. Lekarz POZ. 2020; 4: 3-8.
9. Woroń J. 20 powodów dla których warto zastosować nimesulid. Medycyna Faktów. 2015; 3(28): 81-7.
10. Gaszyński W. Bezpieczeństwo stosowania preferencyjnych inhibitorów COX-2 NLPZ w bólu ostrym. Praktyka lekarska – dodatek specjalny; wrzesień 2013: 2-3.
11. Kocot-Kępska M. Etorykoksyb – nowe możliwości leczenia bólu. Skuteczność i bezpieczeństwo terapii. Reumatologia News. 2017; 3(2): 1-10.
12. Institute for Health and care Excellence. Low back pain and sciatica in over 16s: assessment and management. NICE guideline [NG50]. November 2016.
13. Arend-Nielsen L, Egsgaard LL, Petersen KK. Evidence for central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthrosis. Pain. 2016; 157: 1634-44.